Premier Biomedical, Inc. headquartered in El Paso, TX, in collaboration with The University of Texas in El Paso report that they have a breast cancer therapy that outperforms chemotherapy in mice. They report that mice using this protocol have higher survival rates, smaller tumor volume and maintain weight unlike control mice who were on standard chemotherapy who lose weight.
Most notable about the study is that no mouse treated with Premier Biomedical’s therapy developed metastatic cancer. Of the mice who were given traditional therapies in the study, 20 percent presented with metastases to the lung. The number one cause of death in humans with metastatic breast cancer is systemic body wasting. The results of this study provides evidence that Premier Biomedical’s protocol may be useful as an immune-system-modulating therapy before metastatic complications arise.
Full details will be released in Molecular Cancer Therapeutics in the upcoming weeks. The release will cover methodologies and validate the statistical significance of their results. The journal article will also discuss a subset of the researchers study where mice primed with Premier’s protocol who where then subjected to new tumor cells failed to develop cancer.
According to William A. Hartman, President and Chief Executive Officer of Premier Biomedical, Inc., “This confirmation of results is a positive indication of Premier Biomedical’s ability to bring desperately needed therapy to patients in need. If our breast cancer treatment regimen can successfully prevent metastasis in human patients as it has in mice, then the impact of our therapy on survival rates would be profoundly significant. Furthermore, our tests verify that we may not only have developed an effective therapy against pre-existing breast cancer, but may also have discovered an effective means of preventing breast cancer recurrence that needs more targeted development. This may be an industry first against the threat of breast cancer.”
Read other breast cancer research news:
[feed url=”http://bionews-tx.com/news/news-tags/breast-cancer/feed” number=”5″ ]
Hartman notes, the success of Biomedical’s therapy over conventional treatments suggests he should apply for a Section 902 (Breakthrough Therapy) fast-track designation from the U.S. Food and Drug Administration (FDA) when preliminary human clinical trials are finished.